Oncalis and ChemDiv entered into an R&D collaboration to discover candidates inhibiting receptor tyrosine kinase and other cancer-related targets. Oncalis will apply its yeast cell-based technology and develop biological assays, and ChemDiv will apply its medicinal chemistry and in vitro and in vivo biology services.
ChemDiv provided the source for leads to the yeast-based screening platform that is now completely acquired by Oncalis, together with a high-throughput screening platform and IP rights on research projects.